AMSTERDAM, The Netherlands and BOSTON, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Leyden Laboratories B.V. (the “Company” or “Leyden Labs”), today announces the development of an intranasal spray protecting against influenza A and influenza B based on the human monoclonal antibody CR9114. Leyden Labs has entered into an exclusive licensing agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize CR9114 for mucosal administration. CR9114 is a human monoclonal antibody that protects against both influenza A and B in preclinical models. With the exclusive license to mucosal administration of CR9114, Leyden Labs is developing easy-to-use products that provide immediate protection against contracting and spreading multiple strains of influenza. This supports Leyden Labs’ mission to optimize mucosal protection against entire viral families to prevent future pandemics.